Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.58 |
| ▸ | CCKAR | P32238 | 2/20 | 0.58 |
| ▸ | OXTR | P30559 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005228 | 1.00 | CCKBR (0.68) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6006715 | 1.00 | CCKBR (0.68) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6005992 | 0.95 | CCKBR (0.62) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6003889 | 0.95 | CCKBR (0.62) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6005755 | 0.94 | CCKBR (0.61) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL7097812 | 0.94 | CCKBR (0.61) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6006377 | 0.94 | CCKBR (0.61) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6005648 | 0.93 | PSEN1 (0.65) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6006388 | 0.93 | CCKBR (0.61) | CCKBRKCNH2SCN9ACCKAROXTR | |
| SCHEMBL6006657 | 0.93 | CCKBR (0.61) | CCKBRKCNH2SCN9ACCKAROXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | CCKBR 642/4885KCNH2 1795/4885SCN9A 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.